3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Non-Small-Cell Lung
47
Neoplasms
21
Breast Neoplasms
19
Triple Negative Breast Neoplasms
16
Melanoma
15
Urinary Bladder Neoplasms
14
Carcinoma, Transitional Cell
14
Carcinoma, Hepatocellular
13
Small Cell Lung Carcinoma
11
Ovarian Neoplasms
11
Neoplasm Metastasis
11
Colorectal Neoplasms
11
Uterine Cervical Neoplasms
10
Squamous Cell Carcinoma of Head and Neck
8
Solid Tumors
6
Head and Neck Neoplasms
6
Carcinoma, Renal Cell
6
Lymphoma
5
Esophageal Neoplasms
5
Stomach Neoplasms
4
Lung Neoplasms
4
Kidney Neoplasms
4
Sarcoma
3
Pancreatic Neoplasms
3
Lymphoma, Large B-Cell, Diffuse
3
Lymphoma, Follicular
3
Endometrial Neoplasms
3
Biliary Tract Neoplasms
3
Urologic Neoplasms
2
Solid Tumor
2
Interventions
pemigatinib
4
infigratinib
1
erdafitinib
1
derazantinib
1
atezolizumab
1
Rogaratinib
1
INCB 54828-101
1
Drug Combinations
1
Alpelisib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Acrocephalosyndactylia
×
atezolizumab
×
Clear all
NCT04045613
2023-10-13
FIDES-02
Basilea Pharmaceutica
Phase 1/2
Completed
95 enrolled
25 charts